The reconstituted preparation results in a colorless to pale yellow transparent solution. Parenteral drug CONFIDENTIAL Page 26 of 102 Protocol: HERCEPTIN® + E75/GM-CSF Version 3.1 ML25749 05 March 2017 products should be inspected visually for particulates and discoloration prior to administration. No incompatibilities between Herceptin and polyvinylchloride or polyethylene bags have been observed. c. Administration Treatment may be administered in an outpatient setting by administration of a 8 mg/kg Herceptin loading dose by IV infusion over 90 minutes. DO NOT ADMINISTER AS AN IV PUSH OR BOLUS. If Herceptin is being administered concomitantly with chemotherapy, Herceptin administration should precede chemotherapy administration. Patients should be observed for fever and chills or other infusion-associated symptoms (see ADVERSE REACTIONS). If prior infusions are well tolerated subsequent doses of 6 mg/kg Herceptin q3wk (a window of +/- 3 days is permitted) may be administered over 30 minutes. Table 1 Herceptin Infusion Time and Post-Infusion Observation Period Herceptin Dose Infusion Time (minutes) Post-Infusion Observation Period (minutes) First infusion 8 mg/kg 90 60 Second infusion 6 mg/kg 30 a 30 a Third and subsequent infusions 6 mg/kg 30 a None a a Only if previous dose was well tolerated. Herceptin should not be mixed or diluted with other drugs.